Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2014
06/17/2014US8753884 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
06/17/2014US8753641 Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
06/17/2014US8753633 Human antibodies that bind human TNFα
06/17/2014CA2725014C Inhibitors of pi3 kinase
06/17/2014CA2714942C Stabilized single-liquid pharmaceutical composition containing docetaxel
06/17/2014CA2690828C Composition containing microrna-21 inhibitor for enhancing radiation sensitivity
06/17/2014CA2644649C Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
06/17/2014CA2630273C Heterocyclylalkyl derivatives as inhibitors of histone deacetylase
06/17/2014CA2603347C Oil-in-water emulsions of lignans that exhibit improved absorption rate
06/17/2014CA2595848C Erastin and erastin binding proteins, and uses thereof
06/13/2014CA2799804A1 P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16ink4a expressing tumors
06/13/2014CA2799803A1 Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
06/12/2014WO2014089507A1 Fgf-10 complexes
06/12/2014WO2014089450A1 Specific inhibitors of cdk3
06/12/2014WO2014089416A1 Compositions comprising anti-cd38 antibodies and lenalidomide
06/12/2014WO2014089379A1 Compounds useful as inhibitors of atr kinase
06/12/2014WO2014089354A1 Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
06/12/2014WO2014089335A2 Bcma antigen binding proteins
06/12/2014WO2014089269A1 Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
06/12/2014WO2014089193A1 Anti-fgfr2 antibodies
06/12/2014WO2014089127A1 Combination therapy for treating her2-positive cancers
06/12/2014WO2014089113A1 Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
06/12/2014WO2014089067A2 Use of capsazepine and analogs thereof to treat cancer
06/12/2014WO2014089048A1 Treatment of cancer with heterocyclic inhibitors of glutaminase
06/12/2014WO2014089004A1 Methods for treating 5-fluorouracil prodrug non-responsive cancer patients
06/12/2014WO2014088785A1 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
06/12/2014WO2014088657A1 C20'-urea derivatives of vinca alkaloids
06/12/2014WO2014088520A1 Usage of fig fruit extract and olive leaf extract combinations together with green tea and grape seed extracts
06/12/2014WO2014088519A1 Compounds including map kinase interacting kinases 1 and 2 (mnk1 and mnk2) modulators and abl and abl (t315i) inhibitors, and uses thereof
06/12/2014WO2014088435A1 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii
06/12/2014WO2014088434A1 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
06/12/2014WO2014088432A1 Conjugate compounds
06/12/2014WO2014088349A1 Pvo copolymer and pvo microsphere including same
06/12/2014WO2014088281A1 Novel method for preparing cabazitaxel from 10-deacetylbaccatin iii in high yield, and novel intermediate therefor
06/12/2014WO2014087863A1 Anti-folr1 antibody
06/12/2014WO2014087810A1 Anti-vasohibin 2 antibody
06/12/2014WO2014087778A1 Tumor cell selective anticancer agent including hydroxyalkylated cyclodextrin
06/12/2014WO2014087626A1 Sema5b peptides and vaccines containing the same
06/12/2014WO2014087429A1 Histidinylated cationic amphiphiles, process for preparation thereof and their liposomal formulation
06/12/2014WO2014087230A1 Use of eribulin in the treatment of breast cancer
06/12/2014WO2014087165A1 Tankyrase inhibitors
06/12/2014WO2014086964A1 New derivatives of indole for the treatment of cancer, viral infections and lung diseases
06/12/2014WO2014086952A1 Conjugates of the b-subunit of shiga toxin for anticancer therapies
06/12/2014WO2014086790A1 Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
06/12/2014WO2014086704A1 Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
06/12/2014WO2014086667A1 Substituted isoxazole amine compounds as inhibitors of scd1
06/12/2014WO2014086480A1 Lignan compositions
06/12/2014WO2014086478A1 Inhibitors of malt1 protease
06/12/2014WO2014086379A1 Lignan compositions
06/12/2014WO2014086284A1 Deuterated 3-cyano quinoline compound, pharmaceutical composition, preparation method and use thereof
06/12/2014WO2014086127A1 Doxorubicin conjugate medicine and preparation method thereof
06/12/2014WO2014086102A1 Indole full ketone derivative used as tyrosine-kinase inhibitor
06/12/2014WO2014086032A1 Substituted pyridopyrazines as syk inhibitors
06/12/2014WO2014085909A1 Methods and kits for monitoring response to radiation therapies in cancer
06/12/2014WO2014064652A3 Stable pharmaceutical composition of peginterferon alpha-2b
06/12/2014WO2014062733A3 Substituted benzene compounds
06/12/2014WO2013192274A9 Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
06/12/2014WO2013186690A3 Radiolabeled analog(s) of compound 0118 and use thereof in connection with pet and/or spect imaging to determine whether a pharmaceutical containing compound 0118 is a candidate cancer treatment for a patient
06/12/2014US20140162356 Monoclonal antibodies with enhanced adcc function
06/12/2014US20140161887 Adjuvant compositions
06/12/2014US20140161816 Anti- tnf antibodies, compositions, methods and uses
06/11/2014EP2741226A1 Magnetically guidable compound
06/11/2014EP2740798A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740796A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740795A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740794A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740793A1 Drug composition for cancer treatment and/or prevention
06/11/2014EP2740742A1 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
06/11/2014EP2740739A1 Agrocybe aegerita lectin aal-2, and encoding gene thereof, preparation method therefor and application thereof
06/11/2014EP2740738A1 Platinum compounds for treating cell proliferative disease, preparation methods and uses thereof
06/11/2014EP2740733A1 MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway
06/11/2014EP2740729A1 Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
06/11/2014EP2740493A1 Conjugates of the B-subunit of Shiga toxin for anticancer therapies
06/11/2014EP2740489A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
06/11/2014EP2740477A1 Method for treating cancer by combined use of medicinal agents
06/11/2014EP2740474A1 Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
06/11/2014EP2739738A1 Use of integrase for targeted gene expression
06/11/2014EP2739639A1 Polymorphs of cddo ethyl ester and uses thereof
06/11/2014EP2739618A1 Quinazoline compounds as serine/threonine kinase inhibitors
06/11/2014EP2739617A1 Spirocyclic molecules as protein kinase inhibitors
06/11/2014EP2739616A1 Pyridin-2(1h)-one derivatives as jak inhibitors
06/11/2014EP2739607A1 Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
06/11/2014EP2739358A1 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
06/11/2014EP2739314A1 Pharmaceutical composition of oxidised avidin suitable for inhalation
06/11/2014EP2739310A1 Improved methods and compositions for modulation of olfml3 mediated angiogenesis
06/11/2014EP2739285A1 Selective inhibition of malt1 protease by phenothiazine derivatives
06/11/2014EP2739284A1 Crizotinib for use in the treatment of cancer
06/11/2014EP2739279A2 Novel aniline derivatives and use thereof
06/11/2014EP2739268A1 Method and formulation for inhalation
06/11/2014EP2739262A2 Use of a cb1 receptor antagonist as a whitening and/or anti-browning agent for keratin material
06/11/2014CN103857675A Metalloenzyme inhibitor compounds
06/11/2014CN103857657A Heterocyclic derivative and pharmaceutical drug
06/11/2014CN103857406A Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
06/11/2014CN103857402A Composition comprising anaerobically cultivated human intestinal microbiota
06/11/2014CN103857395A Combinations of AKT inhibitor compounds and abiraterone, and methods of use
06/11/2014CN103849652A Nano carrier compound for microRNA (Ribonucleic Acid) targeting delivery and preparation method and application thereof
06/11/2014CN103848856A Camptothecin derivative with antineoplastic activity
06/11/2014CN103848840A Camptothecin derivatives and medical application thereof
06/11/2014CN103848838A c-Met-VEGFR-2 double antagonist, preparation method and medical use thereof
06/11/2014CN103848833A Pyrrolotriazines derivative, its preparation method and application of pyrrolotriazines derivative on medicine
1 ... 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 ... 2211